New drug combo for advanced pancreatic cancer
Part of Cancer clinical trials.
This trial tests a combination of chemotherapy plus two targeted drugs (serplulimab and bevacizumab) against chemotherapy alone for pancreatic cancer that cannot be removed by surgery or has spread. This approach may help shrink or stabilize the tumor longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic cancer that has spread or cannot be removed by surgery
- You are between 18 and 75 years old
- You have not had any prior chemotherapy or other systemic treatment for this cancer
- You are in generally good health (able to do daily activities, with good organ function)
- You do not have active infections or serious heart/lung problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (serplulimab, bevacizumab, and a chemotherapy regimen) for people with pancreatic cancer that has spread or cannot be removed. It is for those who have already had one prior treatment and aims to see if this new combination can help control the cancer.
This study tests a new combination of two drugs for advanced pancreatic cancer. It aims to see if adding an immunotherapy drug (which helps your immune system attack cancer) to standard chemotherapy can help control the cancer better.
This trial tests a combination of three drugs—anlotinib, benmelstobart, and chemotherapy—as a first treatment for pancreatic cancer that has spread. The goal is to see if this combo can shrink tumors or slow the cancer's growth better than current options.
This study tests a new drug (MRG004A) for advanced pancreatic cancer that has not responded to earlier treatments. The drug is given together with best supportive care (treatments to manage symptoms), and compared to a placebo (a dummy treatment) with best supportive care. The goal is to see if the new drug can slow down the cancer and help you live longer.
This trial tests a new drug combo (cadonilimab plus either S-1 or capecitabine) for people with advanced pancreatic cancer that has not spread to other organs and who have already tried one standard treatment. The goal is to see if this combination can help shrink or control the cancer.
This trial compares two combinations of chemotherapy drugs for people with advanced pancreatic cancer whose first treatment stopped working. The study tests whether adding oxaliplatin and bevacizumab to liposomal irinotecan works better than a standard combination.
Hear when a new Non-Resectable Pancreas Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.